Quality of Life Endpoints in Advanced Gastrointestinal Cancer Trials: Systematic Review of Inclusion, Challenges, and Implications (2020-2024).

S Kalantri¹, B Kelley², J Q Freeman³, T O Akhiwu⁴, R Redman⁵

¹Division of Medical Oncology & Hematology, Brown Cancer Center, University of Louisville, Louisville, KY, USA. Electronic address: shreyas.kalantri@louisville.edu.

²Department of Internal Medicine, University of Louisville, Louisville, USA.

³Department of Public Health Sciences, University of Chicago, Chicago, IL, USA; Cancer Prevention and Control Research Program, UChicago Medicine Comprehensive Cancer Center, Chicago, IL, USA; Center for Health and the Social Sciences, University of Chicago, Chicago, IL, USA.

⁴Department of Medicine, MedStar Health Union Memorial Hospital, Baltimore, MD, USA.

⁵Division of Medical Oncology & Hematology, Brown Cancer Center, University of Louisville, Louisville, KY, USA.

PubMed PMC DOI PDF

Abstract

AIM: Advanced gastrointestinal (GI) cancers negatively impact patients' quality of life (QoL). Incorporating QoL endpoints is essential for holistic therapeutic assessment. This systematic review investigated QoL inclusion in advanced GI cancer phase III clinical trials and its associated factors. METHODS: A PubMed search identified 3795 articles published between January 2020 and December 2024.…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.